Merck & Co., Inc. MRK.BA Stock
Merck & Co., Inc. Price Chart
Merck & Co., Inc. MRK.BA Financial and Trading Overview
| Merck & Co., Inc. stock price | 26341 ARS |
| Previous Close | 10862.5 ARS |
| Open | 11048 ARS |
| Bid | 11049 ARS x 0 |
| Ask | 11100 ARS x 0 |
| Day's Range | 10984 - 11085 ARS |
| 52 Week Range | 4126 - 11509.5 ARS |
| Volume | 491 ARS |
| Avg. Volume | 379 ARS |
| Market Cap | 69.24T ARS |
| Beta (5Y Monthly) | 0.357746 |
| PE Ratio (TTM) | 0.87601805 |
| EPS (TTM) | 1212.57 ARS |
| Forward Dividend & Yield | 95.01 (0.85%) |
| Ex-Dividend Date | March 14, 2023 |
| 1y Target Est | N/A |
MRK.BA Valuation Measures
| Enterprise Value | 494.42B ARS |
| Trailing P/E | 0.87601805 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1196.4113 |
| Price/Book (mrq) | 4796.662 |
| Enterprise Value/Revenue | 8.544 |
| Enterprise Value/EBITDA | 22.105 |
Trading Information
Merck & Co., Inc. Stock Price History
| Beta (5Y Monthly) | 0.357746 |
| 52-Week Change | 155.49% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11509.5 ARS |
| 52 Week Low | 4126 ARS |
| 50-Day Moving Average | 10551.88 ARS |
| 200-Day Moving Average | 7907.54 ARS |
MRK.BA Share Statistics
| Avg. Volume (3 month) | 379 ARS |
| Avg. Daily Volume (10-Days) | 354 ARS |
| Shares Outstanding | 253.74M |
| Float | 20.28B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.8 |
| Trailing Annual Dividend Yield | 0.025% |
| 5 Year Average Dividend Yield | 145.00% |
| Payout Ratio | 0.0111 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 22.51% |
| Operating Margin (ttm) | 32.31% |
| Gross Margin | 72.75% |
| EBITDA Margin | 38.65% |
Management Effectiveness
| Return on Assets (ttm) | 10.89% |
| Return on Equity (ttm) | 29.69% |
Income Statement
| Revenue (ttm) | 57.87B ARS |
| Revenue Per Share (ttm) | 2.85 ARS |
| Quarterly Revenue Growth (yoy) | -8.90% |
| Gross Profit (ttm) | 42.08B ARS |
| EBITDA | 22.37B ARS |
| Net Income Avi to Common (ttm) | 13.03B ARS |
| Diluted EPS (ttm) | 12632.73 |
| Quarterly Earnings Growth (yoy) | -34.50% |
Balance Sheet
| Total Cash (mrq) | 10.39B ARS |
| Total Cash Per Share (mrq) | 0.51 ARS |
| Total Debt (mrq) | 30.75B ARS |
| Total Debt/Equity (mrq) | 65.55 ARS |
| Current Ratio (mrq) | 1.444 |
| Book Value Per Share (mrq) | 2.307125 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 15.67B ARS |
| Levered Free Cash Flow (ttm) | 9.5B ARS |
Profile of Merck & Co., Inc.
| Country | Argentina |
| State | NJ |
| City | Rahway |
| Address | 126 East Lincoln Avenue |
| ZIP | 07065 |
| Phone | 908 740 4000 |
| Website | https://www.merck.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | 67000 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Q&A For Merck & Co., Inc. Stock
What is a current MRK.BA stock price?
Merck & Co., Inc. MRK.BA stock price today per share is 26341 ARS.
How to purchase Merck & Co., Inc. stock?
You can buy MRK.BA shares on the Buenos Aires exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Merck & Co., Inc.?
The stock symbol or ticker of Merck & Co., Inc. is MRK.BA.
Which industry does the Merck & Co., Inc. company belong to?
The Merck & Co., Inc. industry is Drug Manufacturers-General.
How many shares does Merck & Co., Inc. have in circulation?
The max supply of Merck & Co., Inc. shares is 10.48B.
What is Merck & Co., Inc. Price to Earnings Ratio (PE Ratio)?
Merck & Co., Inc. PE Ratio is 21.72328400 now.
What was Merck & Co., Inc. earnings per share over the trailing 12 months (TTM)?
Merck & Co., Inc. EPS is 1212.57 ARS over the trailing 12 months.
Which sector does the Merck & Co., Inc. company belong to?
The Merck & Co., Inc. sector is Healthcare.